These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 28544564)

  • 1. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.
    Fu R; Guo C; Wang S; Huang Y; Jin O; Hu H; Chen J; Xu B; Zhou M; Zhao J; Sung SJ; Wang H; Gaskin F; Yang N; Fu SM
    Arthritis Rheumatol; 2017 Aug; 69(8):1636-1646. PubMed ID: 28544564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation.
    Guo C; Fu R; Zhou M; Wang S; Huang Y; Hu H; Zhao J; Gaskin F; Yang N; Fu SM
    J Autoimmun; 2019 Sep; 103():102286. PubMed ID: 31133359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of Notch1 Signaling Alleviated Podocyte Injury in Lupus Nephritis Via Inhibition of NLRP3 Inflammasome Activation.
    Wu D; Jiang T; Zhang S; Huang M; Zhu Y; Chen L; Zheng Y; Zhang D; Yu H; Yao G; Sun L
    Inflammation; 2024 Apr; 47(2):649-663. PubMed ID: 38085465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice.
    Zhao J; Wang H; Huang Y; Zhang H; Wang S; Gaskin F; Yang N; Fu SM
    Arthritis Rheumatol; 2015 Apr; 67(4):1036-44. PubMed ID: 25512114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia.
    Zhang C; Boini KM; Xia M; Abais JM; Li X; Liu Q; Li PL
    Hypertension; 2012 Jul; 60(1):154-62. PubMed ID: 22647887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus.
    Ferreira NS; Bruder-Nascimento T; Pereira CA; Zanotto CZ; Prado DS; Silva JF; Rassi DM; Foss-Freitas MC; Alves-Filho JC; Carlos D; Tostes RC
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis.
    Chen FF; Liu XT; Tao J; Mao ZM; Wang H; Tan Y; Qu Z; Yu F
    Clin Immunol; 2023 Feb; 247():109221. PubMed ID: 36610524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis.
    Lv F; He Y; Xu H; Li Y; Han L; Yan L; Lang H; Zhao Y; Zhao Z; Qi Y
    Cell Death Dis; 2022 Aug; 13(8):729. PubMed ID: 35999224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podocyte NLRP3 Inflammasome Activation and Formation by Adipokine Visfatin.
    Koka S; Xia M; Zhang C; Zhang Y; Li PL; Boini KM
    Cell Physiol Biochem; 2019; 53(2):355-365. PubMed ID: 31385664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway.
    Zhao J; Wang H; Dai C; Wang H; Zhang H; Huang Y; Wang S; Gaskin F; Yang N; Fu SM
    Arthritis Rheum; 2013 Dec; 65(12):3176-85. PubMed ID: 24022661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim-1 as a Therapeutic Target in Lupus Nephritis.
    Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
    Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin-interacting protein (TXNIP) during hyperhomocysteinemia.
    Abais JM; Xia M; Li G; Chen Y; Conley SM; Gehr TWB; Boini KM; Li PL
    J Biol Chem; 2014 Sep; 289(39):27159-27168. PubMed ID: 25138219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.